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Abstract
Thyroid cancer may have a familial predisposition but a specific germline alteration responsible for the disease has
not been discovered yet. We have shown that familial papillary thyroid cancer (FPTC) patients have an imbalance
in telomere-telomerase complex with short telomeres and increased telomerase activity. A germline mutation
(A339V) in thyroid transcription factor-1 has been described in patients with multinodular goiter and papillary thyr-
oid cancer. In this report, the presence of the A339V mutation and the telomere length has been studied in FPTC
patients and unaffected family members. All samples analyzed displayed a pattern typical of the homozygous wild
type revealing the absence of the A339V mutation. Shortening of telomeres was confirmed in all patients. We con-
cluded that the A339V mutation in thyroid transcription factor-1 (TITF-1/NKX2.1) is not correlated with the familial
form of PTC, even when the tumor was in the context of multinodular goiter.
Findings
Familial non-medullary thyroid cancer (FNMTC), most
frequently of papillary hystotype (FPTC), recurs in two
or more members of the same family in about 10% of
the patients. The clinical form of PTC may be part of a
clinical syndrome such as the Adenomatous polyposis of
colon (FAP) [1], Cowden syndrome [2], Gardner syn-
drome [3], Werner syndrome [4] or Carney complex [5]
or may be the only disease manifestation. In this case,
the large majority of FPTC, no candidate gene(s) has
been discovered [6]. Recently we provided evidence that
F P T Cd i s p l a yt h ef e a t u r eo f“genetic anticipation”
(defined as earlier age at onset of the disease and/or
increased severity in successive generations), and, at
molecular level, are characterized by the presence of
germinal alterations in the telomere-telomerase complex
[7,8]. Our hypothesis is that the imbalance in telomerase
complex may predispose to acquire a thyroid specific
mutation able to trigger thyroid tumorigenesis. Recently,
Ngan et al. demonstrated the presence of a new germ-
line mutation (A339V) in thyroid transcription factor-1
(TITF-1/NKX2.1) in patients with multinodular goiter
and papillary thyroid cancer [9]. The authors identified
the mutation in four out of 20 MNG/PTC patients
which developed more advanced tumors compared to
MNG/PTC or PTC patients without the mutation. In
addition, the mutation was dominantly inherited in two
families with members bearing MNG/PTC [9].
In light of these evidences, we investigated the pre-
sence of A339V mutation in patients with the occur-
rence of FPTC and short telomeres. Out of 408
patients affected by differentiated thyroid carcinoma
(DTC), followed in the Section of Endocrinology of
University of Siena (Italy) from 1978 to 2009 (306
females and 102 males; ratio F/M: 3/1, ranging 8-84
yrs), 63 patients (15.4%), belonging to 38 kindred,
showed the familial recurrence of the disease possibly
configuring the features of familial thyroid cancer
(FTC). All patients with FTC had the papillary hysto-
type (FPTC), 15 of them (23.8%) presented the follicu-
lar variant and 1 (1.6%) the warthin-like variant. Of
these patients, 40 (63.4%) had a parent-child relation-
ship (22 kindred), 19 (30.2%) had a sibling relationship
(13 kindred) and 4 (6.4%) had an uncle-niece relation-
ship (3 kindred). Age at diagnosis of FPTC group was
46 ± 15.5 yrs (range: 15-78 yrs). Age at diagnosis of
probands was 54.3 ± 9.3 (range 25-77 yrs) and that of
affected familial members was 42.9 ± 15.7 (range 15-73
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sent clinically in our patients. Clinical features of
FPTC patients are reported in Table 1. In addition, we
analyzed 41 unaffected family members of FPTC
patients (14 males and 27 females, mean age: 44.4 ± 19
yrs, range: 14-62 yrs) belonging to 25 kindred. Among
FPTC patients, 23 (36.5%) had a single nodule whereas
40 (63.5%) patients had a history of multinodular goi-
t e r .A tt h et i m eo ft h es t u d y4 5( 7 1 . 4 % )w e r ef r e eo f
disease, 12 (19.1%) showed persistent disease and 6
(9.5%) were operated less than 1 year ago (follow-up
not available). In the group of 41 unaffected family
members, 33 (80.6%) patients had no evidence of thyr-
oid nodule, 4 (9.7%) showed a multinodular goiter and
4 (9.7%) had a single nodule. In all cases the FNAB
indicated the presence of benign lesions. We measured
telomere length by Q-PCR [10] assay on genomic
DNA of all subjects and compared the differences in
telomere length by Student’st - t e s t .A ss h o w ni nf i g u r e
1, RTL was significantly (p < 0.0001) shorter in FPTC
patients (mean ± SD: 0.8 ± 0.04, range: 0.18-2.4) com-
pared to unaffected siblings (mean ± SD: 2.04 ± 0.2,
range: 0.7-7.6). To identify whether TITF/NKX2.1
germline point mutation (A339V) was involved with
FPTC development, genomic DNA belonging to FPTC
patients and unaffected siblings, was amplified using
the GC-Rich PCR system followed by digestion of PCR
products by restriction enzyme NaeI. This enzyme cut
in correspondence of 5’-GCCGGC-3’ sequence thus
leading to the formation of these patterns: A) homozy-
gous wild type characterized by three fragments of
421, 197 and 148 bp, respectively; B) mutated homozy-
gous characterized by two PCR products of 618 and
148 bp, respectively and C) heterozygous characterized
by four fragments at 618, 421, 197 and 148 bp, respec-
tively. As shown in figure 2A, after digestion with the
enzyme all the analyzed samples displayed a pattern
typical of homozygous wild type. To confirm this
Table 1 Clinical features of FPTC patients
Patients (n = 63)
Age at diagnosis (yr)
Mean ± SD 46 ± 15.5
Range 15-78
Sex
No. of females (%) 47 (74.6)
No. of males (%) 16 (25.4)
Histotype
No. of papillary (%) 47 (74.6)
No. of papillary follicular variant (%) 15 (23.8)
No. of papillary warthin-like (%) 1 (1.6)
TNM
No. of T1-T3 N0 M0(%) 40 (63.5)
No. of T1-T3 N1 M0 (%) 13 (20.6)
No. of T1-T3 N0-N1 M1 (%) 1 (1.6)
No. of T4 N0-N1 M0 (%) 3 (4.7)
Not available 6 (9.6)
Outcome
Remission (%) 45 (71.4)
Persistent disease (%) 12 (19.1)
Not evaluated (%) 6 (9.5)
Figure 1 RTL expressed as T/S of 63 FPTC patients compared to 41 unaffected siblings Statistic by Student’s t-test (A).
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directly sequenced. As reported in figure 2B no muta-
tion was found in all samples.
In conclusions, in this study we analyzed 63 FPTC
patients for the presence of the A339V mutation in
thyroid transcription factor-1 (TITF-1/NKX2.1) in order
to correlate that mutation with the predisposition to
develop familial form of thyroid cancer demonstrated by
shorter telomere length which may contribute to genetic
instability and thyroid cancer development. Our results
confirmed that FPTC patients have significantly short
telomeres compared to unaffected family members. The
reason of the predisposition to develop thyroid cancer
in patients displaying the imbalance in telomerase com-
plex has not been identified yet. The A339V mutation
in thyroid transcription factor-1 (TITF-1/NKX2.1) might
be a candidate gene in view of recent findings [9]. All
FPTC patients displayed a genetic profile typical of
homozygous wild type demonstrating that A339V muta-
tion is not necessarily associated with the development
of familial form of thyroid cancer even when the tumor
was in the context of multinodular goiter.
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